Format

Send to

Choose Destination
J Neurooncol. 2003 Aug-Sep;64(1-2):71-6.

Survivin in brain tumors: an attractive target for immunotherapy.

Author information

1
Laboratory of Tumor Immunology, Division of Oncology, University Hospital of Geneva, Geneva, Switzerland.

Abstract

Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, both in vitro and in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.

PMID:
12952288
DOI:
10.1007/bf02700022
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center